Skip to main content
SpringerLink
Log in

Cefpirome: another broadsword in the war against severe hospital-acquired infections?

  • New Drugs and Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Wiseman LR, Lamb, HM. Cefpirome: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy in the treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997 Jul; 54(1): 117–40

    Article  PubMed  CAS  Google Scholar 

  2. British National Formulary No. 32. London: The Pharmaceutical Press, 1997 Sep: 241–7

  3. 1997 Physicians GenRx. St Louis, Missouri: Mosby-Year Book, Inc., 1997: pp. II-373–77; II-462–68

  4. Drugs & Therapy Perspectives. Cefepime: a new cephalosporin for parenteral treatment of serious infections. 1994; 4(3): 8 Aug: 4–7

    Google Scholar 

  5. Rains CP, Bryson HM, Peters DH. Ceftazidime: an update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 49: 577–617, 1995

    Article  PubMed  CAS  Google Scholar 

  6. Balfour JA, Bryson HM, Brogden RN. Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Drugs 51: 99–136, 1996

    Article  PubMed  CAS  Google Scholar 

  7. Wolff M, Carbon C, Falissard B, et al. Comparative study of cefpirome (CPO) and ceftazidime (CAZ) in ICU patients with pneumonia [abstract no. LM21]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15–18; New Orleans, USA: 1996; 284

  8. Legall JR, Leleu G, Orvain J, et al. Efficacy of cefpirome in patients with severe pneumonia [abstract]. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1993 Oct 17–20: New Orleans, USA; 1993; 290

  9. Norrby SR, Geddes AM, Shah PM, et al. Cefpirome (CPO) vs ceftazidime (CAZ) as empirical sepsis treatment [abstract no. CE0329]. 20th International Congress of Chemotherapy; 1997 Jun 29-Jul 3; Sydney, Australia

  10. Open, controlled, randomised, multiclinic, comparative study of the efficacy, safety and tolerance of cefpirome (HR810) versus ceftazidime in the empiric treatment of patients with suspected bacteraemia/sepsis. Hoechst Marion Roussel, data on file. HR810/2/MN/302/SP; Feb 14 1997

  11. Norrby SR, Geddes AM. Efficacy of cefpirome in the treatment of septicaemia. Scand J Infect Dis 1993; Suppl. 91: 51–9

    CAS  Google Scholar 

  12. Carbon C, Gonzalez OR, Dictar M, et al. Prospective randomized phase II study of intravenous cefpirome 1g or 2g bd in the treatment of hospitalized patients with different infections. J Antimicrob Chemother 1992 Apr; 29 Suppl. A: 87–94

    PubMed  Google Scholar 

  13. Reiffers J, Cony MP, Pris J, et al. Efficacy of cefpirome in the initial empirical management of febrile neutropenic patients with hematological malignancies [abstract]. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1992 Oct 11–14; Anaheim, USA: 1992; 373

  14. Browett P, Schwarer A, Whitby M, et al. Comparison of cefpirome/gentamicin and piperacillin/gentamicin as empirical therapy for neutropenic fever [abstract]; 1997; data on file

  15. Rubinstein E, Labs R, Reeves A. A review of the adverse events profile of cefpirome. Drug Saf 1993 Nov; 9: 340–5

    Article  PubMed  CAS  Google Scholar 

  16. Cefpirome. Prescrire International 1995 Aug; 4 (18): 110

  17. Vincent J-L, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European prevalence of infection in intensive care study. JAMA 1995; 274: 639–44

    Article  PubMed  CAS  Google Scholar 

  18. Committee of the Scientific Assembly on Microbiology. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and prevention strategies. A consensus statement. Am J Respir Crit Care Med 1995; 153: 1711–25

    Google Scholar 

  19. Glauser M, Boogaerts M, Cordonnier C, et al. Empiric therapy of bacterial infections in severe neutropenia. Clin Microbiol Infect 1997 Apr; 3 Suppl. 1: S77–86

    Article  Google Scholar 

  20. Bodey GP, Nies BA, Mohberg NR, et al. Imipenem/cilastatin therapy of infections in cancer patients. Cancer 1987; 60: 255–62

    Article  PubMed  CAS  Google Scholar 

  21. Sanders JW, Powe NR, Moore RD. Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a metaanalysis. J Infect Dis 1991 Nov; 164: 907–16

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cefpirome: another broadsword in the war against severe hospital-acquired infections?. Drugs Ther. Perspect 11, 1–5 (1998). https://doi.org/10.2165/00042310-199811020-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199811020-00001

Search

Navigation